论文部分内容阅读
〔目的〕研究ki－67单抗标记指数（LabellingIndexLI）在评估侵袭性垂体腺瘤术后复发的作用。［方法］将16例侵袭性垂体腺瘤术后肿瘤标本用ABC法检测ki-67LIl，根据术后随访的复发资料，分复发组（6例）和未复发组（10例）两组，再分析和比较两组的Ki-67LI.[结果]在复发组中的Ki－67LI(63．8土4．5)％显著高于未复发组（21．7土2．3）%，P＜0．01；在所有激素类型中，多激素型的ki－67LI为最高。[结论]你一67LI与侵袭性垂体脉瘤术后复发相关，可作为预测垂体脉瘤术后潜在复发的一项指标。
[Objective] To study the effect of ki-67 monoclonal antibody labeling index (LabellingIndexLI) on the recurrence of invasive pituitary adenomas. [Method] 16 cases of invasive pituitary adenoma tumor specimens were detected by ABC method ki-67LIl, according to the follow-up recurrence data, divided recurrence group (6 cases) and no recurrence group (10 cases) two groups, and then Analysis and comparison of Ki-67LI in the two groups. [Results] Ki-67LI (63.8 ± 4.5%) in the relapse group was significantly higher than that in the non-recurrence group (21.7 ± 2.3%), P < 0.01; Among all hormone types, the poly-hormone type ki-67LI is the highest. [Conclusion] You-67LI is associated with postoperative recurrence of invasive pituitary tumor, which can be used as an index to predict the potential recurrence of pituitary tumor after surgery.